Trial Profile
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Trametinib (Primary) ; Uprosertib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 27 Aug 2019 Status changed from active, no longer recruiting to completed.
- 03 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Dec 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.